• Puromycin Aminonucleoside: Precision Podocyte Injury Modelin

  2026-07-15

  Puromycin aminonucleoside enables robust, reproducible podocyte injury and nephrotic syndrome models, empowering mechanistic and translational nephrology research. This article details stepwise protocols, advanced workflow innovations, and troubleshooting strategies that maximize data quality and reliability.

• Inflammation-Targeted EPO mRNA Nanoparticles Inhibit Ferropt

  2026-07-15

  This study introduces a mannose-modified lipid nanoparticle system for targeted delivery of human erythropoietin mRNA to inflamed spinal cord tissue, addressing the limitations of traditional EPO therapies in spinal cord injury (SCI). By modulating both inflammation and ferroptosis, the approach demonstrates substantial improvements in neuroprotection and functional recovery, offering a promising strategy for translational neurorepair research.

• NF 340: P2Y11 Antagonist Empowering GPCR Signaling Research

  2026-07-14

  NF 340 stands out as a potent and selective P2Y11 antagonist, enabling precise modulation of purinergic signaling in inflammation and cancer invasion models. This article delivers actionable protocols, advanced use-cases, and troubleshooting strategies—backed by recent mechanistic studies and APExBIO’s commitment to reagent reliability.

• Cy5 NHS ester(Et): Practical Guide for Protein Fluorescent L

  2026-07-14

  Cy5 NHS ester(Et) enables efficient, water-soluble fluorescent labeling of primary amines in proteins and biomolecules for detection applications such as immunofluorescence, flow cytometry, and fluorescence microscopy. This reagent is not suitable for ethanol-based workflows or protocols requiring long-term storage of dissolved dye solutions. Following precise dissolution and handling steps ensures consistent labeling and reproducible results.

• CDK9 Inhibitor (A3294): Technical Protocols and Workflow Use

  2026-07-13

  The CDK9 inhibitor (A3294) provides researchers with a selective, non-cytotoxic tool for targeting cyclin dependent kinase 9 in studies of transcription elongation and HIV-1 propagation. It is unsuitable for protocols requiring broad-spectrum CDK inhibition or long-term storage of working solutions. Proper solubility and handling are essential for reproducible application.

• Iron Stress Reprograms Enterocyte Metabolism and Inflammatio

  2026-07-13

  Navazesh and Ji (2025) demonstrate how both iron deficiency and excess distinctly rewire metabolism and inflammatory gene expression in enterocytes. Their use of IPEC-J2 cells and untargeted metabolomics provides new mechanistic insight into the cellular effects of iron imbalance, informing future research on intestinal health and iron chelation strategies.

• Gramine: Unlocking Ferroptosis Pathways in Cancer Biology Re

  2026-07-12

  Gramine (1-(1H-indol-3-yl)-N,N-dimethylmethanamine) empowers advanced cancer biology research by enabling precise dissection of ferroptosis and MTDH ubiquitination pathways. With high purity and validated mechanism-of-action, it stands out as an essential tool for triple-negative breast cancer studies and translational assay development.

• Brassinolide: Mechanistic Leverage and Translational Roadmap

  2026-07-10

  This thought-leadership article decodes the emerging value of Brassinolide (24-Epibrassinolide) as a mechanistically rich tool at the plant–biomedicine interface. By examining recent findings on root regulation in Arabidopsis, integrating validated apoptosis and metabolic assays, and mapping out competitive and translational best practices, we provide strategic guidance for researchers seeking reproducibility and cross-domain impact. Compared with existing reviews, this piece uniquely bridges protocol insight and mechanistic nuance with actionable, scenario-based recommendations for cancer and diabetes models.

• Genomic-Driven Sequencing in Waldenström Macroglobulinemia T

  2026-07-09

  This article reviews a pivotal study that establishes a genomic-guided approach for sequencing therapies in Waldenström macroglobulinemia (WM), emphasizing the roles of MYD88 and CXCR4 mutations in personalizing treatment. The findings highlight the clinical significance of integrating molecular profiling into therapeutic decision-making and provide actionable insights for translational cancer research.

• Nadolol (SQ-11725) for Hypertension and Vascular Research Wo

  2026-07-09

  Nadolol (SQ-11725) stands out as a robust, non-selective beta-adrenergic blocker essential for translational cardiovascular studies. Its dual function as a beta-adrenergic antagonist and a defined OATP1A2 substrate supports reproducible modeling of hypertension, angina pectoris, and headache syndromes.

• Exendin-4 (Exenatide): Applied Workflows for Diabetes Resear

  2026-07-08

  Exendin-4 empowers researchers to precisely model insulin sensitivity, beta cell function, and hepatic steatosis reversal in both in vitro and in vivo systems. This article translates cutting-edge production advances and robust workflows into actionable protocols, enabling scientists to optimize reproducibility and troubleshoot common bottlenecks in type 2 diabetes research.

• SP600125: Selective JNK Inhibitor for Inflammation Research

  2026-07-08

  SP600125 empowers researchers to dissect JNK-dependent inflammation and cytokine regulation with nanomolar selectivity, enabling robust, reproducible results in both cell-based and in vivo studies. With a workflow-friendly profile and deep literature support, this JNK inhibitor stands out for troubleshooting complex signaling assays and advancing translational inflammation research.

• Stat3 and NF-κB Synergy Drives Fyn Kinase Neurodegeneration

  2026-07-07

  This study establishes Stat3 as a novel effector in Fyn kinase-driven dopaminergic neurodegeneration and microglial activation, leveraging a zebrafish model. By demonstrating the synergy between Stat3 and NF-κB pathways, the research clarifies key mechanisms underlying Parkinsonian neurodegeneration and identifies potential targets for intervention.

• Oxaliplatin Synergy: Mechanistic Insights & Translational Im

  2026-07-07

  Explore how Oxaliplatin’s DNA-damaging mechanisms and strategic low-dose orlistat combinations are reshaping translational research and clinical paradigms in metastatic colorectal cancer. This thought-leadership article provides actionable guidance for researchers, integrating mechanistic depth, experimental validation, and forward-looking recommendations, while highlighting the rigor and versatility of APExBIO’s Oxaliplatin.

• LLY-507: Potent SMYD2 Inhibitor for Cancer and Fibrosis Rese

  2026-07-06

  LLY-507 is a highly selective SMYD2 inhibitor with nanomolar potency, enabling precise interrogation of lysine methylation in cancer and fibrotic disease models. Its ability to block SMYD2-mediated methylation of p53 and histone substrates underpins key applications in apoptosis and cancer cell proliferation inhibition research.

447 records 11/30 page Previous Next First page 上5页 1112131415 下5页 Last page